ESTRO 2024 - Abstract Book

S1774

Clinical - Lung

ESTRO 2024

Median follow-up was 32m for period 1 and 18m for period 2.

1yOS, 2yOS was 74%, 59% for period 1 and 87%, 77% for period 2, respectively (p0.015).

1yCSS, 2yCSS was 86%, 65% for period 1 and 96%, 91% for period 2, respectively (p0.001).

1yPFS, 2yPFS was 78%, 61% for period 1 and 90%, 81.4% for period 2, respectively (p0.235).

1yLPFS, 2yLPFS was for 93%, 81% for period 1 and 96% for period 2, respectively (p0.05).

Conclusion:

First of all, it should be noted that there has been a relevant increase in patients treated with SBRT. Secondly, in period 2 OS, CSS and LPFS have increased, probably related to improvements in the SBRT technique. The increased prominence of RTTs in these treatments has not affected the results, and may even have influenced the improvement. It should be taken into account that these results may be influenced by the lower follow-up in Period 2 and by the increase in treatments without cytological confirmation.

Keywords: SBRT, survival, treatment changes

2742

Digital Poster

Cardiac condition unchanged after SBRT near the heart for NSCLC; results of prospective HALO trial

Wiert Hoeksema 1 , Jose Belderbos 2 , Edith Dieleman 3 , Krista van Doorn-Wink 4 , H.A.C.M de Bruin-Bon 1 , Martijn van der Ree 1 , Jorrit Visser 3 , Zdenko van Kesteren 3 , Pieter Postema 1 , S. Matthijs Boekholdt 1 , R. Nils Planken 5 , Jan-Jakob Sonke 2 , Barbara Stam 2 1 Amsterdam UMC, Department of Cardiology, Amsterdam, Netherlands. 2 Netherlands Cancer Institute, Department of Radiation Oncology, Amsterdam, Netherlands. 3 Amsterdam UMC, Department of Radiation Oncology, Amsterdam, Netherlands. 4 LUMC, Department of Radiation Oncology, Leiden, Netherlands. 5 Amsterdam UMC, Department of Radiology and nuclear medicine, Amsterdam, Netherlands

Purpose/Objective:

Cardiac toxicity in non-small cell lung cancer (NSCLC) patients after radiation has been a subject of interest since the results of the RTOG 0617 revealed an association between cardiac dose and survival [1]. Several studies have shown similar associations between cardiac dose and survival or a cardiac event. In most studies, these toxicities were collected retrospectively and a baseline cardiac evaluation was not performed, while other cardiotoxic agents such as chemotherapy were present. In this study, we prospectively evaluate cardiac toxicity after stereotactic body